Cargando…

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies have investigated novel therapeutic agents for IPF, but very few have addressed their comparative benefits an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rochwerg, Bram, Neupane, Binod, Zhang, Yuan, Garcia, Carlos Cuello, Raghu, Ganesh, Richeldi, Luca, Brozek, Jan, Beyene, Joseph, Schünemann, Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741055/ https://www.ncbi.nlm.nih.gov/pubmed/26843176 http://dx.doi.org/10.1186/s12916-016-0558-x

Ejemplares similares

Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?
por: Rochwerg, Bram, et al.
Publicado: (2016)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

Reply to Moran-Mendoza: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Raghu, Ganesh, et al.
Publicado: (2022)

The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory
por: Raghu, Ganesh, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis: pathogenesis and management
por: Sgalla, Giacomo, et al.
Publicado: (2018)

Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
por: Cottin, Vincent, et al.
Publicado: (2014)

Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
por: Raghu, Ganesh
Publicado: (2017)

Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
por: Spagnolo, Paolo, et al.
Publicado: (2012)

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Multivariate Meta-Analysis of Genetic Association Studies: A Simulation Study
por: Neupane, Binod, et al.
Publicado: (2015)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report
por: Cerri, Stefania, et al.
Publicado: (2016)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
por: Collard, Harold R, et al.
Publicado: (2013)

Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics
por: Costabel, U, et al.
Publicado: (2013)

Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2021)

Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis
por: Wallis, Tim JM, et al.
Publicado: (2022)

Network Meta-Analysis Using R: A Review of Currently Available Automated Packages
por: Neupane, Binod, et al.
Publicado: (2014)

Bivariate linear mixed model analysis to test joint associations of genetic variants on systolic and diastolic blood pressure
por: Neupane, Binod, et al.
Publicado: (2014)

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
por: Costabel, Ulrich, et al.
Publicado: (2018)

Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis)
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study
por: Raghu, Ganesh, et al.
Publicado: (2022)

Testing for associations between systolic blood pressure and single-nucleotide polymorphism profiles obtained from sparse principal component analysis
por: Bonner, Ashley, et al.
Publicado: (2014)

Empirical evaluation of SUCRA-based treatment ranks in network meta-analysis: quantifying robustness using Cohen’s kappa
por: Daly, Caitlin H, et al.
Publicado: (2019)

Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis
por: Jones, Mark G., et al.
Publicado: (2016)

New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases
por: Azuma, Arata, et al.
Publicado: (2020)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
por: Raghu, Ganesh, et al.
Publicado: (2022)

GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis
por: Gobbo, Francesca, et al.
Publicado: (2023)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bqvbbac4dgroenmq8hugvlv476